trial · primary record
Inotuzumab ozogamicin (INO)
B-Cell Acute Lymphoblastic Leukaemia
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 750 |
| Primary completion | 2033-03-31 |
| Primary endpoint | SR induction EFS |
| Registry ID | NCT07476729 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:15.810Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07476729
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.